Galasso Linda, Cerrito Lucia, Termite Fabrizio, Mignini Irene, Esposto Giorgio, Borriello Raffaele, Ainora Maria Elena, Gasbarrini Antonio, Zocco Maria Assunta
Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, 00168 Rome, Italy.
CEMAD Digestive Disease Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, 00168 Rome, Italy.
Cancers (Basel). 2024 Sep 24;16(19):3247. doi: 10.3390/cancers16193247.
Hepatocellular carcinoma (HCC) represents the sixth most diagnosed cancer worldwide and is the second leading cause of cancer-related death in the world. The association of HCC and portal vein thrombosis (PVT) represents an advanced stage of the tumor. PVT has a prevalence of about 25-50% in HCC, determining poor prognosis and a remarkable reduction in therapeutic perspectives in these patients, leading to severe complications such as ascites, metastasis, an increase in portal hypertension and potentially fatal gastrointestinal bleeding. The aim of this review is to evaluate the molecular mechanisms that are at the basis of PVT development, trying to evaluate possible strategies in the early detection of patients at high risk of PVT.
肝细胞癌（HCC）是全球第六大最常被诊断出的癌症，也是全球癌症相关死亡的第二大主要原因。HCC与门静脉血栓形成（PVT）的关联代表肿瘤的晚期阶段。PVT在HCC中的患病率约为25%-50%，这决定了这些患者的预后不良以及治疗前景的显著降低，导致诸如腹水、转移、门静脉高压增加以及潜在致命的胃肠道出血等严重并发症。本综述的目的是评估PVT发生所基于的分子机制，试图评估在早期检测PVT高风险患者方面的可能策略。
